AI-generated summary
The authors conducted a scoping review of nine studies examining extraoral photobiomodulation for preventing or treating oral mucositis in oncology patients. Three studies were rated as OCEBM level 2 and six as level 4. The authors report limited evidence for exclusive use of extraoral photobiomodulation, with mixed results against sham, placebo, or no treatment.
- Studies included
- 9
- Who or what was studied
- Oncologic patients with oral mucositis or at risk of developing it
- Limits stated in the abstract
- The authors state that the current level of evidence for exclusive extraoral protocols remains limited, and the evidence base includes mostly low-level studies with varying results.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Oral mucositis, Randomized controlled trial, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.